Somatostatin receptor
1 EU-approved indication of 1 drug needs a Somatostatin receptor result, in 1 tumour type, most of them in neuroendocrine tumours.
Approved indications1
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| Neuroendocrine tumours1 | ||||
Lutathera | Monotherapy | Any line advanced | Gastroenteropancreatic NET only; Progressive; well-differentiated (G1 and G2) | |
Somatostatin receptor by tumour
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Lutetium (177Lu) oxodotreotide (Lutathera)
Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.